$1.19 Billion is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 116 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SNY | SANOFIsponsored adr | $40,660,000 | -8.5% | 843,400 | 0.0% | 3.42% | +13.7% | |
| MSFT | MICROSOFT CORP | $19,040,000 | +4.1% | 67,536 | 0.0% | 1.60% | +29.3% | |
| BIIB | BIOGEN INCcall | $14,149,000 | -18.3% | 50,000 | 0.0% | 1.19% | +1.5% | |
| TEVA | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $8,112,000 | -1.6% | 832,878 | 0.0% | 0.68% | +22.2% | |
| CSTE | CAESARSTONE LTD | $8,000,000 | -15.9% | 644,146 | 0.0% | 0.67% | +4.5% | |
| BLSA | BCLS ACQUISITION CORP | $6,879,000 | -5.0% | 687,900 | 0.0% | 0.58% | +18.0% | |
| VRNT | VERINT SYS INC | $6,719,000 | -0.6% | 150,000 | 0.0% | 0.56% | +23.4% | |
| RACB | RESEARCH ALLIANCE CORP II | $5,910,000 | -1.5% | 600,000 | 0.0% | 0.50% | +22.4% | |
| STRO | SUTRO BIOPHARMA INC | $5,569,000 | +1.6% | 294,825 | 0.0% | 0.47% | +26.1% | |
| QURE | UNIQURE NV | $5,506,000 | +3.9% | 172,000 | 0.0% | 0.46% | +29.3% | |
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $4,912,000 | -39.2% | 800,000 | 0.0% | 0.41% | -24.5% | |
| VRNA | VERONA PHARMA PLCsponsored ads | $4,391,000 | -16.2% | 801,256 | 0.0% | 0.37% | +4.2% | |
| EUCR | EUCRATES BIOMEDICAL ACQU COR | $3,218,000 | -0.6% | 329,025 | 0.0% | 0.27% | +23.3% | |
| ARGX | ARGENX SEsponsored adr | $2,793,000 | +0.3% | 9,249 | 0.0% | 0.24% | +25.0% | |
| CYCC | CYCLACEL PHARMACEUTICALS INC | $2,679,000 | -11.0% | 508,322 | 0.0% | 0.22% | +10.3% | |
| RPTX | REPARE THERAPEUTICS INC | $2,634,000 | -15.8% | 100,391 | 0.0% | 0.22% | +4.2% | |
| CVRX | CVRX INC | $2,481,000 | -40.9% | 150,000 | 0.0% | 0.21% | -26.8% | |
| TMPM | TURMERIC ACQUISITION CORPcl a | $2,148,000 | -1.0% | 219,440 | 0.0% | 0.18% | +22.4% | |
| JYAC | JIYA ACQUISITION CORP | $1,946,000 | -1.6% | 199,028 | 0.0% | 0.16% | +21.6% | |
| LVTX | LAVA THERAPEUTICS NV | $1,275,000 | -45.6% | 215,359 | 0.0% | 0.11% | -32.3% | |
| FLAC | FRAZIER LIFESCIENCES ACQU CO | $1,244,000 | +0.6% | 126,687 | 0.0% | 0.10% | +25.0% | |
| OMEG | OMEGA ALPHA SPACcl a | $974,000 | -2.1% | 100,000 | 0.0% | 0.08% | +22.4% | |
| NICE SYS INCnote 1.250% 1/1 | $846,000 | +15.7% | 250,000 | 0.0% | 0.07% | +44.9% | ||
| CMLTU | CM LIFE SCIENCES III INCunit 04/30/2028 | $769,000 | -6.3% | 75,000 | 0.0% | 0.06% | +16.1% | |
| IMTXW | IMMATICS N.V*w exp 07/01/202 | $423,000 | +23.0% | 100,000 | 0.0% | 0.04% | +56.5% | |
| SRSA | SARISSA CAPITAL ACQUISITN COcl a | $236,000 | -0.4% | 23,900 | 0.0% | 0.02% | +25.0% | |
| OTLKW | OUTLOOK THERAPEUTICS INC*w exp 02/18/202 | $26,000 | -46.9% | 129,500 | 0.0% | 0.00% | -33.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.